Clinical Trials
Neurophet Secures Third FDA Clearance For AI Driven Alzheimer’s Imaging Platform
Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based Alzheimer's disease imaging analysis Advanced ...
February 09, 2026 | News
Imagion Biosystems Files FDA IND For MagSense Molecular MRI Cancer Imaging Platform
Imagion Biosystems, Ltd. (ASX: IBX) announced that the company has lodged an Investigational New Drug (IND) application with the U.S. Food and Drug Adminis...
February 06, 2026 | News
Australian World First Paediatric mRNA Brain Cancer Trial Signals Expansion Opportunity For Canada And The United States
Landmark Australian study opens new possibilities for children with aggressive brain tumors and signals opportunity for Canada and USA. -- Providence Ther...
February 06, 2026 | News
Everest Medicines Secures Exclusive Asia Pacific Rights To First In Class Dual Target SHPT Therapy MT1013
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturi...
February 06, 2026 | News
Biosion Doses First Patient In Phase 1 Trial Of Novel Anti SIRPα Antibody BSI 082
Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In...
February 05, 2026 | News
Insilico Medicine Receives $5 Million Milestone From Menarini Group After First Patient Dosed In Phase 1 Trial Of AI Designed Cancer Therapy
Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone paymen...
February 05, 2026 | News
SanegeneBio Licenses RNAi Programme To Genentech In Global Deal Valued Up To USD 1.7 Billion
SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million up...
February 04, 2026 | News
Ascletis Pharma Reports Positive Phase III Safety Results For Denifanstat In Moderate To Severe Acne
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label ...
February 03, 2026 | News
MicuRx Pharmaceuticals Receives FDA IND Clearance For MRX 5 In Mycobacterium abscessus Pulmonary Disease
MicuRx Pharmaceuticals, Inc. ("MicuRx"), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant...
February 03, 2026 | News
DHL Group Strengthens Asia Pacific Healthcare Logistics With €10 Million Pharmaceutical Hub In Singapore
Strategic expansion positions Singapore as a strategic arm for healthcare logistics in the APAC region. DHL Group invests €10 million in a new phar...
February 02, 2026 | News
Turning Frontline Reality Into Policy Action For Cancer Care In Asia
Drawing on her frontline clinical experience in Malaysia, Prof Dr Wan Zamaniah, Consultant Clinical Oncologist, University Malaya Medical Centre&...
February 02, 2026 | Expert Insight
Closing Asia’s Cancer Evidence Gap Through Translational Science And Policy Leadership
In this BioPharma APAC interview, Dr Yun Yen, Program Committee Chair for the 2026 ASCO Breakthrough meeting, shares a candid translational...
February 02, 2026 | Expert Insight
China Approves World First cAMP Biased GLP One Receptor Agonist For Type Two Diabetes
Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic disea...
February 02, 2026 | News
China Originated Innovation Is Rising. Global Expectations Are Rising Even Faster.
The momentum is real—and so is the level of scrutiny. As more programs move beyond regional boundaries, expectations from global biopharma companies ...
February 02, 2026 | News | By Anil Kane, executive director, global head of technical and scientific affairs, Thermo Fisher Scientific
Most Read
- How Does GLP-1 Work?
- Innovations In Magnetic Resonance Imaging Introduced By United Imaging
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
